Beta-Adrenergic Modulation of Drug Cue Reactivity

Description

This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.

Conditions

Tobacco Use Disorder, Nicotine Dependence, Cigarette Smoking

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.

Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms

Beta-Adrenergic Modulation of Drug Cue Reactivity

Condition
Tobacco Use Disorder
Intervention / Treatment

-

Contacts and Locations

Tulsa

Hardesty Center for Clinical Research and Neuroscience, Tulsa, Oklahoma, United States, 74136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Generally healthy
  • 2. Age 21-60
  • 3. Right-handed using a three-item scale
  • 4. Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC)
  • 5. Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months
  • 6. Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and/or morning urinary cotinine \>100 ng/ml
  • 7. Must identity at least 4 different smoking locations used in a typical week
  • 8. Able to read and understand English
  • 1. Inability to attend all required sessions
  • 2. Significant health problems that would preclude active participation
  • 3. Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape)
  • 4. Current use of psychoactive medications/drugs as indicated by self-report or urine screen
  • 5. Positive breath alcohol concentration
  • 6. Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females)
  • 7. Problems with vision that cannot be corrected with contacts or glasses
  • 8. Current regular use of smokeless tobacco, smoking cessation medications, or other nicotine containing products (e.g. electronic cigarettes)
  • 9. Current use of beta-adrenergic medications (e.g. beta-blockers) or other blood pressure medications
  • 10. Systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg (sitting or standing)
  • 11. Abnormal EKG
  • 12. Presence of severe anemia
  • 13. Presence of electrolyte imbalance that could impact blood pressure
  • 14. Presence of any other contraindications for propranolol or nicotine patch (e.g. cardiovascular disease, bronchial asthma, prior allergic reactions, diabetes)

Ages Eligible for Study

21 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Oklahoma,

Jason A Oliver, PhD, PRINCIPAL_INVESTIGATOR, University of Oklahoma

Study Record Dates

2025-03-30